XKRX
144510
Market cap163mUSD
Oct 08, Last price
14,600.00KRW
1D
-3.44%
1Q
3.77%
Jan 2017
-41.48%
IPO
-76.64%
Name
GC Cell Corp
Chart & performance
P/E
—
P/S
1.33
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.35%
Rev. gr., 5y
14.11%
Revenues
165.52b
-5.12%
Net income
-258.94b
L+250.39%
CFO
4.96b
-56.28%
Dividend
Dec 27, 2023100 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. It offers cell therapy products, cell banking, clinical laboratory services, clinical trials, and bio logistics. The company was founded on June 21, 2011, and is headquartered in Yongin-si, South Korea.
Key people
Jae Wang Kim
Co-Chief Executive Officer, Director · since 2025
Seong Cheol Choi
Internal Auditor · since 2024
Jin Hui Kang
Assistant Managing Director · since 2024
Wu Bong Kang
Assistant Managing Director · since 2025
Chang Hwi Lee
Assistant Managing Director · since 2024
Dong Yil Park
Assistant Managing Director
Jun Yeol Yang
Assistant Managing Director · since 2025
Hong Gi Bae
Non-Executive Independent Director · since 2021
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||